182 related articles for article (PubMed ID: 37813567)
1. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
[TBL] [Abstract][Full Text] [Related]
2. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
Choi WM; Kim GA; Choi J; Han S; Lim YS
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
[TBL] [Abstract][Full Text] [Related]
3. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
[TBL] [Abstract][Full Text] [Related]
4. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
Kim GA; Han S; Choi GH; Choi J; Lim YS
Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.
Li J; Dong XQ; Cao LH; Zhang ZQ; Zhao WF; Shang QH; Zhang DZ; Ma AL; Xie Q; Gui HL; Zhang G; Liu YX; Shang J; Xie SB; Liu YQ; Zhang C; Wang GQ; Zhao H;
Front Cell Infect Microbiol; 2023; 13():1151899. PubMed ID: 37396307
[TBL] [Abstract][Full Text] [Related]
6. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
7. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
8. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
11. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y
J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343
[TBL] [Abstract][Full Text] [Related]
12. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
13. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
[TBL] [Abstract][Full Text] [Related]
14. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
15. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
17. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
Choi GH; Kim GA; Choi J; Han S; Lim YS
Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
[TBL] [Abstract][Full Text] [Related]
18. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.
Wang J; Zhu L; Zhang S; Zhang Z; Fan T; Cao F; Xiong Y; Pan Y; Li Y; Jiang C; Yin S; Tong X; Xiong Y; Xia J; Yan X; Liu Y; Liu X; Chen Y; Li J; Zhu C; Wu C; Huang R
Emerg Microbes Infect; 2024 Dec; 13(1):2339944. PubMed ID: 38584592
[TBL] [Abstract][Full Text] [Related]
20. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
